BeiGene, Ltd. (NASDAQ:BGNE), a clinical-stage biopharmaceutical
company developing innovative molecularly targeted and
immuno-oncology drugs for the treatment of cancer, today announced
that it will present updates on its BTK inhibitor BGB-3111 in three
oral presentations and a poster at the upcoming 14th International
Conference on Malignant Lymphoma (14-ICML). 14-ICML will take place
June 14-17, 2017, in Lugano, Switzerland. Following its
presentations, BeiGene will host an investor call and webcast to
discuss the presented data and development program.
Oral Presentation, Abstract # 059
Title: Bruton’s Tyrosine Kinase (BTK) Inhibitor
BGB-3111 Demonstrates High Very Good Partial Response (VGPR) Rate
in Patients with Waldenström Macroglobulinemia (WM)
Presenter: Dr. Judith Trotman
Session: Session 4 - Targeting the BCR
PathwaysDate & Time: Thursday, June 15, 2017,
4:00 PM CESTLocation: Room A, Cinema Corso and
Aula Magna (Lugano University)
Oral Presentation, Abstract # OT06
Title: A Head-to-Head Phase 3 Study Comparing
BGB-3111 and Ibrutinib in Patients with Waldenström
Macroglobulinemia
Presenter: Dr. Christian Buske
Session: Ongoing TrialsDate &
Time: Thursday, June 15, 2017, 6:05 PM
CESTLocation: Auditorium (Lugano University)
Oral Presentation, Abstract # 103
Title: Safety and Activity of the Highly
Specific BTK Inhibitor, BGB-3111 Plus Obinutuzumab in Patients
(Pts) with Follicular Lymphoma (FL) and Chronic Lymphocytic
Leukemia (CLL)
Presenter: Dr. Constantine Tam
Session: Session 7 - Advances in
CLLDate & Time: Friday, June 16, 2017, 11:50
AM CESTLocation: Room A, B, Marquee, Cinema Corso
and Aula Magna (Lugano University)
Poster, Abstract # 237
Title: High Overall Response Rate with the BTK
Inhibitor BGB-3111 in Patients with Chronic Lymphocytic Leukemia /
Small Lymphocytic Lymphoma: An Update on Safety and Activity
Presenter: Dr. John Seymour
Session Dates & Times: Wednesday, June 14,
12:30-6:30 PM CEST; Thursday, June 15, 8:30-6:30 PM CEST; Friday,
June 16, 8:30-6:30 PM CESTLocation: Marquee
Investor Conference Call
Date & Time: Friday, June 16, 2017, 2:00 PM
CEST (8:00 AM EDT, 8:00 PM China Standard Time)
Dial-in Numbers: 1-845-675-0437 or
1-866-519-4004 (US), 400-620-8038 or 800-819-0121 (China), +852
30186771 (Hong Kong), or +65 67135090 (International)
Conference ID Number: 33044427
A live webcast and replay will be available on BeiGene’s
investor website, http://ir.beigene.com/. The dial-in replay will
be available approximately two hours after the conference and will
be available for two days following the event. It can be accessed
by dialing 1-646-254-3697 (US), 400-632-2162 (China), +852 30512780
(Hong Kong), or +61 2 8199 0299 (International).
About BGB-3111
BGB-3111 is a potent and highly selective investigational small
molecule inhibitor of BTK. BGB-3111 has demonstrated higher
selectivity against BTK than ibrutinib (the only BTK inhibitor
currently approved by the U.S. Food and Drug Administration and the
European Medicines Agency) based on biochemical assays, higher
exposure than ibrutinib based on their respective Phase I
experience, and sustained 24-hour BTK occupancy in both the blood
and the lymph node.
About BeiGene
BeiGene is a global, clinical-stage, research-based
biotechnology company focused on molecularly targeted and
immuno-oncology cancer therapeutics. With a team of over 400
employees in mainland China, the United States, and Australia,
BeiGene is advancing a pipeline consisting of novel oral small
molecules and monoclonal antibodies for the treatment of cancer.
BeiGene is working to create combination solutions aimed at having
both a meaningful and lasting impact on cancer patients.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of 1995
and other federal securities laws, including statements regarding
the encouraging preclinical and clinical data of BGB-3111. Actual
results may differ materially from those indicated in the
forward-looking statements as a result of various important
factors, including BeiGene's ability to demonstrate the efficacy
and safety of its drug candidates; the clinical results for its
drug candidates, which may not support further development; actions
of regulatory agencies, which may affect the initiation, timing and
progress of clinical trials; BeiGene's ability to achieve market
acceptance in the medical community necessary for commercial
success; BeiGene's ability to obtain and maintain protection of
intellectual property for its technology and drugs; BeiGene's
reliance on third parties to conduct preclinical studies and
clinical trials and manufacturing; BeiGene’s limited operating
history and BeiGene's ability to obtain additional funding for
operations and to complete the development and commercialization of
its drug candidates, as well as those risks more fully discussed in
the section entitled “Risk Factors” in BeiGene’s most recent
quarterly report on Form 10-Q, as well as discussions of potential
risks, uncertainties, and other important factors in BeiGene's
subsequent filings with the U.S. Securities and Exchange
Commission. All information in this press release is as of the date
of this press release, and BeiGene undertakes no duty to update
such information unless required by law.
Investor/Media Contact
Lucy Li, Ph.D.
+1 781-801-1800
ir@beigene.com
media@beigene.com
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Mar 2024 to Apr 2024
BeiGene (NASDAQ:BGNE)
Historical Stock Chart
From Apr 2023 to Apr 2024